Pancreatic Cancer Research

ResearcherChiba UniversityActive in the last 2 years

Hideaki Ijichi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2379-7986; OpenAlex author ID A5026907725. Sources: OpenAlex.

Their work

Papers
52 (first author 8, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
77
Papers, trials and grants by year

2011: 2 papers · 2012: 4 papers · 2013: 10 papers · 2014: 5 papers · 2015: 4 papers · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 4 papers · 2020: 2 papers · 2021: 2 papers · 2022: 4 papers · 2023: 4 papers · 2024: 3 papers · 2025: 3 papers · 2026: 3 papers

Papers 50 of 52

  1. Blocking L-carnitine synthesis by meldonium prolongs the survival in mice with pancreatic cancer. First author DOI 10.1016/j.isci.2026.117071↗
  2. High-Dose Tramadol Enhances the Proliferative and Invasive Potential of Pancreatic Ductal Adenocarcinoma in Mice Through Microenvironmental Alteration. Co-author DOI 10.1155/prm/6594413↗
  3. Pregabalin enhances the proliferative potential of pancreatic cancer in vitro but not in mice with pancreatic cancer. Co-author DOI 10.1186/s40360-026-01176-2↗
  4. WWP1 inhibition suppresses the proliferation of pancreatic cancer cells by regulating the PI3K-AKT pathway. Co-author DOI 10.1007/s00535-024-02192-x↗
  5. Duloxetine improves hyperosmia in mice with pancreatic cancer by increasing dopamine levels in the olfactory bulb. Co-author DOI 10.1016/j.biopha.2025.118098↗
  6. Blockade of CC chemokine receptor 2 suppresses pancreatic cancer progression through the interaction with macrophages in the tumor microenvironment. First author DOI 10.1038/s41598-025-32222-4↗
  7. The role of DPYD and the effects of DPYD suppressor luteolin combined with 5-FU in pancreatic cancer. Co-author DOI 10.1002/cam4.70124↗
  8. The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection. Co-author DOI 10.1097/mpa.0000000000002291↗
  9. Effects of tramadol via a µ-opioid receptor on pancreatic ductal adenocarcinoma in vitro and in vivo. Co-author DOI 10.1136/rapm-2023-104511↗
  10. Combination of serum human satellite RNA and miR-21-5p levels as a biomarker for pancreatic cancer. Co-author DOI 10.1016/j.isci.2023.106021↗
  11. Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors. Co-author DOI 10.1016/j.omto.2022.12.001↗
  12. Mirogabalin improves cancer-associated pain but increases the risk of malignancy in mice with pancreatic cancer. Co-author DOI 10.1097/j.pain.0000000000002852↗
  13. Significance of Tumor Microenvironment for Regulating Pancreatic Cancer. Co-author DOI 10.3390/cancers15092482↗
  14. Midazolam exhibits antitumour and anti-inflammatory effects in a mouse model of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bja.2021.12.042↗
  15. The Role of Neural Signaling in the Pancreatic Cancer Microenvironment. First author DOI 10.3390/cancers14174269↗
  16. The Role of the Microbiome in Pancreatic Cancer. First author DOI 10.3390/cancers14184479↗
  17. Multiphasic Heterogeneity of Fibroblasts in the Microenvironment of Pancreatic Ductal Adenocarcinoma: Dissection and the Sum of the Dynamics. Co-author DOI 10.3390/cancers14194880↗
  18. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. Co-author DOI 10.1007/s10637-020-01022-0↗
  19. Protein intake after the initiation of chemotherapy is an independent prognostic factor for overall survival in patients with unresectable pancreatic cancer: A… First author DOI 10.1016/j.clnu.2021.06.011↗
  20. Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. First author DOI 10.1038/s41598-020-78320-3↗
  21. Duloxetine improves cancer-associated pain in a mouse model of pancreatic cancer through stimulation of noradrenaline pathway and its antitumor effects. Co-author DOI 10.1097/j.pain.0000000000001997↗
  22. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s10637-018-0691-9↗
  23. Diagnostic yield of the plasma free amino acid index for pancreatic cancer in patients with diabetes mellitus. Co-author DOI 10.1016/j.pan.2019.07.002↗
  24. Indirubin 3'-Oxime Inhibits Migration, Invasion, and Metastasis InVivo in Mice Bearing Spontaneously Occurring Pancreatic Cancer via Blocking the RAF/ERK, AKT,… Co-author DOI 10.1016/j.tranon.2019.08.010↗
  25. Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invas… First author DOI 10.1038/s41389-018-0117-8↗
  26. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic … Co-author DOI 10.1007/s12032-018-1158-8↗
  27. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Co-author DOI 10.18632/oncotarget.11129↗
  28. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Co-author DOI 10.1007/s00432-014-1873-2↗
  29. Pancreatic cancer with malignant ascites: clinical features and outcomes. Co-author DOI 10.1097/mpa.0000000000000290↗
  30. [IPMN and pancreatic cyst as high risk of pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.1474↗
  31. [Animal model of pancreatic cancer]. Co-author PMID 25856981↗
  32. A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. Co-author DOI 10.1007/s00280-014-2563-0↗
  33. Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. Co-author DOI 10.1007/s12029-014-9603-1↗
  34. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα. Co-author DOI 10.1093/carcin/bgu136↗
  35. Smoking, family history of cancer, and diabetes mellitus are associated with the age of onset of pancreatic cancer in Japanese patients. Co-author DOI 10.1097/mpa.0000000000000158↗
  36. [Development of basic research of pancreatic cancer: from genetically-engineered mouse models to bedside]. Co-author PMID 25100345↗
  37. Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monoth… Co-author DOI 10.1007/s00280-012-1981-0↗
  38. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Co-author DOI 10.1007/s00280-013-2278-7↗
  39. A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer. Co-author DOI 10.1007/s00280-013-2313-8↗
  40. Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. Co-author DOI 10.1007/s00535-012-0622-z↗
  41. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Co-author DOI 10.1007/s10637-013-9972-5↗
  42. Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.03.013↗
  43. Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. Co-author DOI 10.1097/mpa.0b013e31825de678↗
  44. Risk for mortality from causes other than pancreatic cancer in patients with intraductal papillary mucinous neoplasm of the pancreas. Co-author DOI 10.1097/mpa.0b013e318270ea97↗
  45. Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer. Co-author DOI 10.1111/cas.12080↗
  46. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. First author DOI 10.1158/0008-5472.can-12-1453↗
  47. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. Co-author DOI 10.1007/s00535-011-0482-y↗
  48. Engineering fibrotic tissue in pancreatic cancer: a novel three-dimensional model to investigate nanoparticle delivery. Co-author DOI 10.1016/j.bbrc.2012.01.117↗
  49. Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. Co-author DOI 10.1111/j.1349-7006.2012.02311.x↗
  50. Inhibition of CXCLs/CXCR2 axis in the tumor microenvironment might be a potent therapeutics for pancreatic cancer. Co-author DOI 10.4161/onci.19402↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Makoto Sano · 14 shared papers, 2019–2026 · strength 2.64
  2. Kazuhiko Koike · 32 shared papers, 2011–2024 · strength 1.83
  3. Koji Miyabayashi · 25 shared papers, 2011–2026 · strength 1.77
  4. Mitsuhiro Fujishiro · 6 shared papers, 2022–2026 · strength 1.47
  5. Yukino Oshima · 7 shared papers, 2020–2026 · strength 1.47
  6. Yousuke Nakai · 26 shared papers, 2012–2024 · strength 1.45
  7. Tomoaki Itaya · 6 shared papers, 2022–2026 · strength 1.36
  8. Tomoya Kuramochi · 6 shared papers, 2022–2026 · strength 1.36
  9. Ichie Kajiwara · 6 shared papers, 2019–2026 · strength 1.01
  10. Hiroyuki Isayama · 24 shared papers, 2012–2020 · strength 0.98
  11. Yoshimi Ichimaru · 6 shared papers, 2019–2026 · strength 0.95
  12. Takahiro Suzuki · 5 shared papers, 2020–2025 · strength 0.85
  13. Atsushi Masamune · 5 shared papers, 2020–2026 · strength 0.85
  14. Suguru Mizuno · 19 shared papers, 2012–2021 · strength 0.78
  15. Hirofumi Kogure · 19 shared papers, 2012–2021 · strength 0.78
  16. Takahiro Kishikawa · 5 shared papers, 2015–2025 · strength 0.76
  17. Ryota Takahashi · 6 shared papers, 2013–2025 · strength 0.74
  18. Keisuke Yamamoto · 14 shared papers, 2012–2025 · strength 0.70
  19. Minoru Tada · 19 shared papers, 2012–2019 · strength 0.70
  20. Naminatsu Takahara · 16 shared papers, 2013–2021 · strength 0.69
  21. Kazunaga Ishigaki · 8 shared papers, 2015–2023 · strength 0.66
  22. Takahiro Suzuki · 2 shared papers, 2026 · strength 0.62
  23. Gen Kimura · 3 shared papers, 2020–2026 · strength 0.60
  24. Kei Saito · 9 shared papers, 2014–2021 · strength 0.59
  25. Genso Notoya · 2 shared papers, 2025 · strength 0.51

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.